Serum biomarkers in rheumatoid arthritis patients and effect of Unani herbal formulation Qurs-e-Hudar on these biomarkers suggesting the anti-IL-6 effect
Authors:
- Towseef Amin RafeeqiTRTowseef Amin Rafeeqi
- Riyaz Ahmed PandithRPRiyaz Ahmed Pandith
- HummaHUHumma
- Arjumand ShahASArjumand Shah
- Mohammad ZakirMZMohammad Zakir
- Nighat AnjumNANighat Anjum
- Irfat AraIAIrfat Ara
- N. Zaheer AhmedNAN. Zaheer Ahmed
- 7 February 2025
- journal article
- Published by Elsevier in Journal of Herbal Medicine
- Vol. 50
Abstract
No abstract availableFunding Information
- Ministry of AYUSH, Government of India
- Central Council for Research in Unani Medicine (1.04.2019)
This publication has 29 references indexed in Scilit:
- Evaluation of oral and topical herbal formulations used in Unani medicine for treatment of psoriasis and its effect on inflammatory biomarkers – a randomized controlled clinical trialEuropean Journal of Integrative Medicine, 2022
- Topical nanocarriers for management of Rheumatoid Arthritis: A reviewBiomedicine & Pharmacotherapy, 2021
- 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid ArthritisArthritis & Rheumatology, 2021
- Novel nano therapeutic materials for the effective treatment of rheumatoid arthritis-recent insightsMaterials Today Communications, 2018
- CCL19, a B Cell Chemokine, Is Related to the Decrease of Blood Memory B Cells and Predicts the Clinical Response to Rituximab in Patients With Rheumatoid ArthritisArthritis & Rheumatism, 2013
- Circulating levels of tumor necrosis factor receptors are highly predictive of mortality in patients with rheumatoid arthritisArthritis & Rheumatism, 2007
- Double‐blind randomized controlled clinical trial of the interleukin‐6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexateArthritis & Rheumatism, 2006
- C-reactive protein: Ligands, receptors and role in inflammationClinical Immunology, 2005
- Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritisArthritis & Rheumatism, 2003
- Therapeutic benefit of blocking interleukin‐6 activity with an anti–interleukin‐6 receptor monoclonal antibody in rheumatoid arthritis: A randomized, double‐blind, placebo‐controlled, dose‐escalation trialArthritis & Rheumatism, 2002